STVN Stock Analysis: Stevanato | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 5.392m USD | 12M Return: -24.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.57M
EPS Trend: 1.7%
Qual. Beats: 0
Rev. Trend: 97.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Stevanato Group S.p.A. (NYSE: STVN) is an Italy-based provider of drug containment, drug delivery, and diagnostic solutions serving the biopharma and healthcare industries worldwide. Founded in 1949 and headquartered in Piombino Dese, Italy, the company operates through two segments-Biopharmaceutical and Diagnostic Solutions, and Engineering-and is a subsidiary of Stevanato Holding S.R.L.
Its product portfolio spans primary glass packaging (pre-fillable syringes, cartridges, vials, and ampoules), drug delivery devices (pen injectors, auto-injectors, and wearable injectors), in-vitro diagnostic consumables, and pharmaceutical manufacturing equipment such as visual inspection machines, assembling and packaging machines, and glass converting machines. The company also provides analytical and regulatory support, after-sales services, and contract development and manufacturing for customer-owned drug delivery devices.
Stevanatos customer base includes pharmaceutical, biotechnology, diagnostics, and life sciences companies, as well as contract manufacturers involved in fill and finish operations. The company operates on a global footprint, with commercial reach across Europe, the Middle East, Africa, North America, South America, and the Asia Pacific, and has been listed on the NYSE since its IPO in July 2021.
As a supplier of glass primary packaging and integrated device solutions, Stevanato sits within a specialized B2B niche of the healthcare equipment value chain, where customers are highly regulated drug manufacturers with long product life cycles. The company competes in a relatively consolidated market for high-quality tubular glass and pre-sterilized containers, an area where demand is closely tied to trends in biologics, biosimilars, injectable therapies, and self-administration drug delivery formats.
- GLP-1 demand surge drives pre-fillable syringe order growth
- Engineering segment revenue expands on pharmaceutical equipment capex
- Schott and Gerresheimer competition pressures drug containment pricing margins
| Net Income: 140.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 7.21 > 1.0 |
| NWC/Revenue: 29.51% < 20% (prev 33.99%; Δ -4.48% < -1%) |
| CFO/TA 0.10 > 3% & CFO 260.1m > Net Income 140.9m |
| Net Debt (352.4m) to EBITDA (294.2m): 1.20 < 3 |
| Current Ratio: 1.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (273.0m) vs 12m ago 0.04% < -2% |
| Gross Margin: 29.01% > 18% (prev 27.57%; Δ 1.45% > 0.5%) |
| Asset Turnover: 48.90% > 50% (prev 48.39%; Δ 0.51% > 0%) |
| Interest Coverage Ratio: 21.94 > 6 (EBIT TTM 201.9m / Interest Expense TTM 9.20m) |
| A: 0.14 (Total Current Assets 914.4m - Total Current Liabilities 560.3m) / Total Assets 2.58b |
| B: 0.39 (Retained Earnings 1.02b / Total Assets 2.58b) |
| C: 0.08 (EBIT TTM 201.9m / Avg Total Assets 2.45b) |
| D: 1.45 (Book Value of Equity 1.53b / Total Liabilities 1.05b) |
| Altman-Z'' = 4.26 = AA |
| DSRI: 0.97 (Receivables 506.7m/487.6m, Revenue 1.20b/1.12b) |
| GMI: 0.95 (GM 27.57% / 29.01%) |
| AQI: 0.94 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 1.07 (Revenue 1.20b / 1.12b) |
| TATA: -0.05 (NI 140.9m - CFO 260.1m) / TA 2.58b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 19.59 with a total of 318,545 shares traded. Over the past week, the price has changed by +3.11%, over one month by +13.97%, over three months by +45.42% and over the past year by -24.21%.
Current recommended Stop Loss: 18.40 (which is 6.1% or 1.4 ATR below the current price).
Stevanato has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy STVN.
- StrongBuy: 6
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24.5 | 24.8% |
Market Cap EUR = 4.71b (5.39b USD * 0.8737 USD.EUR)
P/E Trailing = 34.0517
P/E Forward = 19.4553
P/S = 4.481
P/B = 3.0256
P/EG = 3.5691
Revenue TTM = 1.20b EUR
EBIT TTM = 201.9m EUR
EBITDA TTM = 294.2m EUR
Long Term Debt = 312.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 124.8m EUR (from shortTermDebt, last quarter)
Debt = 465.1m EUR (from shortLongTermDebtTotal, last quarter) + Leases 16.6m
Net Debt = 352.4m EUR (calculated: Debt 465.1m - CCE 112.7m)
Enterprise Value = 5.06b EUR (4.71b + Debt 465.1m - CCE 112.7m)
Interest Coverage Ratio = 21.94 (Ebit TTM 201.9m / Interest Expense TTM 9.20m)
EV/FCF = -712.6x (Enterprise Value 5.06b / FCF TTM -7.11m)
FCF Yield = -0.14% (FCF TTM -7.11m / Enterprise Value 5.06b)
FCF Margin = -0.59% (FCF TTM -7.11m / Revenue TTM 1.20b)
Net Margin = 11.75% (Net Income TTM 140.9m / Revenue TTM 1.20b)
Gross Margin = 29.01% ((Revenue TTM 1.20b - Cost of Revenue TTM 851.9m) / Revenue TTM)
Gross Margin QoQ = 27.48% (prev 30.85%)
Tobins Q-Ratio = 1.96 (Enterprise Value 5.06b / Total Assets 2.58b)
Interest Expense / Debt = 1.98% (Interest Expense 9.20m / Debt 465.1m)
Taxrate = 26.84% (51.7m / 192.7m)
NOPAT = 147.7m (EBIT 201.9m * (1 - 26.84%))
Current Ratio = 1.63 (Total Current Assets 914.4m / Total Current Liabilities 560.3m)
Debt / Equity = 0.30 (Debt 465.1m / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = 1.20 (Net Debt 352.4m / EBITDA 294.2m)
Debt / FCF = -49.60 (negative FCF - burning cash) (Net Debt 352.4m / FCF TTM -7.11m)
Total Stockholder Equity = 1.46b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.74% (Net Income 140.9m / Total Assets 2.58b)
RoE = 9.63% (Net Income TTM 140.9m / Total Stockholder Equity 1.46b)
RoCE = 11.37% (EBIT 201.9m / Capital Employed (Equity 1.46b + L.T.Debt 312.6m))
RoIC = 7.07% (NOPAT 147.7m / Invested Capital 2.09b)
WACC = 7.09% (E(4.71b)/V(5.18b) * Re(7.65%) + D(465.1m)/V(5.18b) * Rd(1.98%) * (1-Tc(0.27)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 1.25%
[DCF] Fair Price = unknown (Cash Flow -7.11m)
EPS Correlation: 1.70 | EPS CAGR: 0.15% | SUE: 0.48 | # QB: 0
Revenue Correlation: 97.92 | Revenue CAGR: 5.17% | SUE: 0.26 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.15 | Chg30d=-1.07% | Revisions=-50% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.18 | Chg30d=-1.82% | Revisions=-30% | Analysts=10
EPS current Year (2026-12-31): EPS=0.70 | Chg30d=-1.04% | Revisions=-36% | GrowthEPS=+12.1% | GrowthRev=+7.5%
EPS next Year (2027-12-31): EPS=0.84 | Chg30d=-0.65% | Revisions=-55% | GrowthEPS=+18.9% | GrowthRev=+9.7%
[Analyst] Revisions Ratio: -55% (up=6, down=24)